Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 14 min ago
Peer-reviewedCC BY-NC-NDInternal Medicine

Severe Multiorgan Failure Associated with Differentiation Syndrome in a High-risk Acute Promyelocytic Leukemia Patient with Concurrent Influenza A

Abstract

Differentiation syndrome (DS) is rarely observed before treatment in patients with acute promyelocytic leukemia (APL). A 35-year-old man with high-risk APL and influenza A presented with multiple organ failure (MOF). Initially attributed to influenza, the DS-like symptoms rapidly worsened after the initiation of all-trans retinoic acid. Despite intensive care and continuous hemodialysis, the patient developed a cerebral hemorrhage. Consequently, dose-adjusted arsenic trioxide (ATO; 0.1 mg/kg/day) was administered. He achieved complete remission (CR) on day 28 and maintained molecular CR for 16 months without sequelae. Concurrent infections can mask DS-like symptoms prior to treatment. Reduced-dose ATO is an effective salvage option for patients with APL and severe MOF.

Related

  1. Growth Variation in the Pacific Oyster (Crassostrea gigas) Is Associated with Sequential Transcriptional Programs of Tissue Differentiation
    Julan Kim, Hyojung Son, Hee-Jung Lee +11
    International journal of molecular sciencesPeer-reviewedCC BYFull textGeneral biochemistryEurope PMC
  2. Age-Associated Decrease of the Histone Methyltransferase SUV39H1 in HSC Perturbs Heterochromatin and B Lymphoid Differentiation
    Dounia Djeghloul, Klaudia Kuranda, Isabelle Kuzniak +11
    Stem Cell ReportsPeer-reviewedCC BY-NC-NDFull text122 citedMolecular biology & gene regulationHAL
  3. Extramedullary Relapse of Acute Promyelocytic Leukemia in the Middle Ear after All-Trans Retinoic Acid Combined with Chemotherapy
    Noriko Tsuge, Taisuke Kobayashi, Masahiro Komori +8
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textMolecular biology & gene regulationJ-STAGE
  4. Acute Promyelocytic Leukemia with t(11;17)(q23.2;q21.2) Treated with Haploidentical Transplantation Using Post-transplant Cyclophosphamide
    Yujiro Ito, Ayato Sumioka, Ibuki Takatsuka +2
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textMolecular biology & gene regulationJ-STAGE
  5. Human Cardiac Organoids Reveal HAND1 Loss-Associated Alterations in Cell Composition During Early Cardiac Differentiation
    Hao Yang, Yunqian Zeng, Yiyang Teng +5
    CellsPeer-reviewedCC BY 4.0Molecular biology & gene regulationCrossref
BibTeX
@article{yoshimoto2026severe,
  title = {{Severe Multiorgan Failure Associated with Differentiation Syndrome in a High-risk Acute Promyelocytic Leukemia Patient with Concurrent Influenza A}},
  author = {Sunami Yoshimoto and Naoto Imoto and Haruki Koketsu and Tomoyoshi Wakayama and Shun Ukai and Rie Ito and Shingo Kurahashi},
  journal = {Internal Medicine},
  year = {2026},
  month = aug,
  doi = {10.2169/internalmedicine.7565-26},
  url = {https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7565-26/_article},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Severe Multiorgan Failure Associated with Differentiation Syndrome in a High-risk Acute Promyelocytic Leukemia Patient with Concurrent Influenza A
AU  - Sunami Yoshimoto
AU  - Naoto Imoto
AU  - Haruki Koketsu
AU  - Tomoyoshi Wakayama
AU  - Shun Ukai
AU  - Rie Ito
AU  - Shingo Kurahashi
PY  - 2026
DA  - 2026/08/25
JO  - Internal Medicine
DO  - 10.2169/internalmedicine.7565-26
UR  - https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7565-26/_article
AB  - Differentiation syndrome (DS) is rarely observed before treatment in patients with acute promyelocytic leukemia (APL). A 35-year-old man with high-risk APL and influenza A presented with multiple organ failure (MOF). Initially attributed to influenza, the DS-like symptoms rapidly worsened after the initiation of all-trans retinoic acid. Despite intensive care and continuous hemodialysis, the patient developed a cerebral hemorrhage. Consequently, dose-adjusted arsenic trioxide (ATO; 0.1 mg/kg/day) was administered. He achieved complete remission (CR) on day 28 and maintained molecular CR for 16 months without sequelae. Concurrent infections can mask DS-like symptoms prior to treatment. Reduced-dose ATO is an effective salvage option for patients with APL and severe MOF.
SN  - 1349-7235
SN  - 0918-2918
ER  -